{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:04:36Z","timestamp":1789988676746,"version":"4.0.1"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Stenotrophomonas maltophilia is an opportunistic, multidrug-resistant pathogen commonly associated with respiratory and bloodstream infections. Owing to extensive intrinsic and acquired antimicrobial resistance and limited pediatric-specific evidence, contemporary management relies heavily on extrapolation from adult data, underscoring the need to better characterize real-world treatment practices and outcomes in children. This was a retrospective, observational cohort that included hospitalized patients &lt; 18 years of age with a positive S. maltophilia culture who received active antimicrobial therapy, excluding cases determined by the treating provider to represent colonization. Outcomes assessed included in-hospital mortality, adverse drug effects, and clinical success rates using descriptive statistics. Forty pediatric patients (median [IQR] age of 2.7 [0.7\u20137.9] years) were included. Respiratory infections accounted for 77.5% of cases, and sulfamethoxazole-trimethoprim monotherapy was the most common treatment regimen (70.0%). Five patients (12.5%) experienced in-hospital mortality, three patients (7.5%) experienced adverse effects related to treatment, and all patients exhibited clinical success. Larger, multicenter observational and prospective studies are warranted to strengthen evidence-based therapeutic approaches for pediatric patients with S. maltophilia infections.<\/jats:p>","DOI":"10.3390\/microorganisms14092087","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:25:43Z","timestamp":1789986343000},"page":"2087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns and Clinical Outcomes in Children with Stenotrophomonas maltophilia Infections"],"prefix":"10.3390","volume":"14","author":[{"given":"Carly","family":"Mitchell","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Rivera-Agosto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo R.","family":"Alvira-Arill","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA"},{"name":"Department of Pharmacy Services, Medical University of South Carolina Health, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlan J. Kunz","family":"Coyne","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3410-4524","authenticated-orcid":false,"given":"Stephen A.","family":"Thacker","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases, Medical University of South Carolina Health, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3982-2103","authenticated-orcid":false,"given":"Krutika Mediwala","family":"Hornback","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Medical University of South Carolina Health, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-043X","authenticated-orcid":false,"given":"Taylor","family":"Morrisette","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Outcomes Sciences, Medical University of South Carolina College of Pharmacy, Charleston, SC 29425, USA"},{"name":"Department of Pharmacy Services, Medical University of South Carolina Health, Charleston, SC 29425, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/CMR.11.1.57","article-title":"Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia","volume":"11","author":"Denton","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e0003019","DOI":"10.1128\/CMR.00030-19","article-title":"Advances in the Microbiology of Stenotrophomonas maltophilia","volume":"34","author":"Brooke","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e0101124","DOI":"10.1128\/spectrum.01011-24","article-title":"Stenotrophomonas maltophilia bacteremia in adult patients with hematological diseases: Clinical characteristics and risk factors for 28-day mortality","volume":"13","author":"Guo","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/23744235.2024.2324365","article-title":"Risk factors for mortality in Stenotrophomonas maltophilia bacteremia\u2014A meta-analysis","volume":"56","author":"Huang","year":"2024","journal-title":"Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jiac.2018.03.011","article-title":"Risk factors for death from Stenotrophomonas maltophilia bacteremia","volume":"24","author":"Osawa","year":"2018","journal-title":"J. Infect. Chemother. Off. J. Jpn. Soc. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/cid\/ciaa778","article-title":"Alterations of the Oral Microbiome and Cumulative Carbapenem Exposure Are Associated With Stenotrophomonas maltophilia Infection in Patients With Acute Myeloid Leukemia Receiving Chemotherapy","volume":"72","author":"Aitken","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e0039821","DOI":"10.1128\/JB.00398-21","article-title":"Evaluating Metabolic Pathways and Biofilm Formation in Stenotrophomonas maltophilia","volume":"204","author":"Isom","year":"2022","journal-title":"J. Bacteriol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13756-021-00888-w","article-title":"Stenotrophomonas maltophilia bacteremia in children: Risk factors and mortality rate","volume":"10","author":"Alsuhaibani","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gezer, Y., Tay\u015fi, M.R., Tarak\u00e7\u0131, A., G\u00f6k\u00e7e, \u00d6., Danac\u0131, G., Altun\u0131\u015f\u0131k Toplu, S., Erdal Karaka\u015f, E., Alkan, S., Kuyug\u00f6z G\u00fclbudak, S., and \u015eahino\u011flu, M.S. (2024). Evaluation of clinical outcomes and risk factors associated with mortality in patients with Stenotrophomonas maltophilia bloodstream infection: A multicenter study. BMC Infect. Dis., 24, Erratum in BMC Infect. Dis. 2024, 24, 1396.","DOI":"10.1186\/s12879-024-10293-4"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e19250","DOI":"10.1097\/MD.0000000000019250","article-title":"Characteristics of Stenotrophomonas maltophilia infection in children in Sichuan, China, from 2010 to 2017","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"dlac040","DOI":"10.1093\/jacamr\/dlac040","article-title":"Clinical challenges treating Stenotrophomonas maltophilia infections: An update","volume":"4","author":"Mojica","year":"2022","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_12","first-page":"1291","article-title":"How do I manage a patient with Stenotrophomonas maltophilia infection?","volume":"31","author":"Monardo","year":"2025","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Samonis, G., Karageorgopoulos, D.E., Maraki, S., Levis, P., Dimopoulou, D., Spernovasilis, N.A., Kofteridis, D.P., and Falagas, M.E. (2012). Stenotrophomonas maltophilia infections in a general hospital: Patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037375"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/CMR.00019-11","article-title":"Stenotrophomonas maltophilia: An emerging global opportunistic pathogen","volume":"25","author":"Brooke","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00405-19","DOI":"10.1128\/mBio.00405-19","article-title":"Population Structure, Molecular Epidemiology, and \u03b2-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States","volume":"10","author":"Mojica","year":"2019","journal-title":"mBio"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/gb-2008-9-4-r74","article-title":"The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants","volume":"9","author":"Crossman","year":"2008","journal-title":"Genome Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Prawang, A., Chanjamlong, N., Rungwara, W., Santimaleeworagun, W., Paiboonvong, T., Manapattanasatein, T., Pitirattanaworranat, P., Kitseree, P., and Kanchanasurakit, S. (2022). Combination Therapy versus Monotherapy in the Treatment of Stenotrophomonas maltophilia Infections: A Systematic Review and Meta-Analysis. Antibiotics, 11.","DOI":"10.21203\/rs.3.rs-1212986\/v1"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/INF.0000000000001959","article-title":"Management of Stenotrophomonas maltophilia Infections in Critically Ill Children","volume":"37","author":"Paret","year":"2018","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Z\u00f6llner, S.K., Kampmeier, S., Frob\u00f6se, N.J., Herbr\u00fcggen, H., Masjosthusmann, K., van den Heuvel, A., Reicherts, C., Ranft, A., and Groll, A.H. (2021). Stenotrophomonas maltophilia Infections in Pediatric Patients\u2014Experience at a European Center for Pediatric Hematology and Oncology. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.752037"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults","volume":"3","author":"Fernandez","year":"2011","journal-title":"Pharmaceutics"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/AAC.01682-13","article-title":"Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?","volume":"58","author":"Cho","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/jac\/dkv456","article-title":"Monotherapy with minocycline or trimethoprim\/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections","volume":"71","author":"Hand","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/10600280231201850","article-title":"Trimethoprim\/Sulfamethoxazole vs Minocycline for the Treatment of Nonurinary Monomicrobial Stenotrophomonas maltophilia Infections in Hospitalized Patients","volume":"58","author":"Hevia","year":"2024","journal-title":"Ann. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ofab644","DOI":"10.1093\/ofid\/ofab644","article-title":"Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals","volume":"9","author":"Sarzynski","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1093\/jac\/dkac304","article-title":"Trimethoprim\/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model","volume":"77","author":"Lasko","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e0216721","DOI":"10.1128\/aac.02167-21","article-title":"In Vitro Time-Kill Studies of Trimethoprim\/Sulfamethoxazole against Stenotrophomonas maltophilia versus Escherichia coli Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth","volume":"66","author":"Lasko","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/jac\/dkz116","article-title":"Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia","volume":"74","author":"Shah","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","unstructured":"CLSI (2026). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. [36th ed.]. CLSI Supplement M100."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/jac\/dkac018","article-title":"Minocycline pharmacodynamics against Stenotrophomonas maltophilia in the neutropenic murine infection model: Implications for susceptibility breakpoints","volume":"77","author":"Fratoni","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e0061822","DOI":"10.1128\/aac.00618-22","article-title":"Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits","volume":"66","author":"Petraitis","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","unstructured":"CLSI (2025). CLSI Subcomittee on Antimicrobial Susceptibility Testing, CLSI. CLSI AST News Update."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13054-019-2649-5","article-title":"Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: A nationwide retrospective study","volume":"23","author":"Guerci","year":"2019","journal-title":"Crit. Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13613-023-01144-7","article-title":"Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: A multicenter, observational, real-world study","volume":"13","author":"Chen","year":"2023","journal-title":"Ann. Intensive Care"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e01433-20","DOI":"10.1128\/AAC.01433-20","article-title":"Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide","volume":"64","author":"Sader","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e01436-20","DOI":"10.1128\/AAC.01436-20","article-title":"In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia","volume":"65","author":"Nakamura","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00559-20","DOI":"10.1128\/AAC.00559-20","article-title":"Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e0310823","DOI":"10.1128\/spectrum.03108-23","article-title":"Cefiderocol: Early clinical experience for multi-drug resistant gram-negative infections","volume":"12","author":"Lucas","year":"2024","journal-title":"Microbiol. Spectr."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/9\/2087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:43:24Z","timestamp":1789987404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/9\/2087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["microorganisms14092087"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms14092087","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}